Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 combinations in recurrent or metastatic cervical cancer
NCT06859775Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in Cervical Cancer (CC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Apr 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06859775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859775.